HDAC4 promotes nasopharyngeal carcinoma progression and serves as a therapeutic target

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Histone deacetylases (HDACs) are implicated in tumor progression, with some HDACs targeted in cancer therapy.
• Histone deacetylase 4 (HDAC4) is a class IIa HDAC whose role in nasopharyngeal carcinoma (NPC) remains unclear.
• Previous microarray data indicated upregulation of HDAC4 in NPC.

Purpose of the Study:

• To investigate the role and mechanisms of HDAC4 in nasopharyngeal carcinoma (NPC) progression.
• To evaluate HDAC4 as a potential diagnostic marker and therapeutic target in NPC.

Main Methods:

• Confirmation of HDAC4 expression levels in NPC tissues versus normal tissues.
• In vitro and in vivo functional assays to assess HDAC4's impact on NPC cell behavior and tumor growth.
• Investigation of molecular mechanisms involving N-CoR and E-cadherin.
• Evaluation of the therapeutic potential of an HDAC4 inhibitor (tasquinimod).

Main Results:

• HDAC4 expression is significantly upregulated in primary and metastatic NPC tissues.
• High HDAC4 expression correlates with poor overall survival (OS) and progression-free survival (PFS).
• HDAC4 promotes NPC cell proliferation, migration, invasion, tumor growth, and lung metastasis by accelerating cell cycle G1/S transition and inducing epithelial-to-mesenchymal transition.
• HDAC4/HDAC3 complex represses E-cadherin transcription via binding to its promoter.
• Knockdown of N-CoR abrogated HDAC4-mediated invasion and migration.
• Tasquinimod suppressed NPC tumor growth.

Conclusions:

• HDAC4 plays a critical role in promoting NPC progression, including growth and metastasis.
• HDAC4 may serve as a valuable diagnostic biomarker for NPC.
• Targeting HDAC4 with inhibitors like tasquinimod shows therapeutic promise for NPC treatment.